Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma

British Journal of Ophthalmology

Volumn 82, Issue 8, 1998, Pages 961-970

  Coupland, S E ^a,b   Bechrakis, N ^a   Schuler A ^a   Anagnostopoulos, I ^a   Hummel, M ^a   Bornfeld, N ^a   Stein, H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UKBF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; PROTEIN BCL 2; PROTEIN P16; PROTEIN P21; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHILD; CHOROID MELANOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; RETINOBLASTOMA; SCHOOL CHILD; UVEA MELANOMA;

EID: 0031679192     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.82.8.961     Document Type: Article

References (74)

1. Sherr CJ. Mammalian G1 cyclins. Cell 1993;73:1059-65.
2. Dowdy SF, Hinds PW, Louie K, et al. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 1993;73:499-511.
3. Ewen ME, Sluss HK, Sherr CJ, et al. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 1993;73:487-97.
4. Hinds PW, Mittnacht S, Dulic V, et al. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 1992;70:993-1006.
5. Motokura T, Bloom T, Kim HG, et al. A novel cyclin encoded by a bcl1-linked candidate oncogene [see comments]. Nature 1991;350:512-5.
6. Ott MM, Helbing A, Ott G, et al. bcl-1 rearrangement and cyclin D1 protein expression in mantle cell lymphoma. J Pathol 1996;179:238-42.
7. Zukerberg LR, Benedict WF, Arnold A, et al. Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1. Blood 1996;88:268-76.
8. Bartkova J, Lukas J, Strauss M, et al. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 1995;10:775-8.
9. Bartkova J, Lukas J, Muller H, et al. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994;57:353-61.
10. Buckley MF, Sweeney KJ, Hamilton JA, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993;8:2127-33.
11. Kurzrock R, Ku S, Talpaz M. Abnormalities in the PRAD1 (CYCLIN D1/BCL-1) oncogene are frequent in cervical and vulvar squamous cell carcinoma cell lines. Cancer 1995;75:584-90.
12. Mate JL, Ariza A, Aracil C, et al. Cyclin D1 overexpression in non-small cell lung carcinoma: correlation with Ki67 labelling index and poor cytoplasmic differentiation. J Pathol 1996;180:395-9.
13. Michalides R, van Veelen N, Hart A, et al. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995;55:975-8.
14. Naitoh H, Shibata J, Kawaguchi A, et al. Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J Pathol 1995;146:1161-9.
15. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995;86: 841-54.
16. Hunter T, Pines J. Cyclins and cancer. Cell 1991;66:1071-4.
17. Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age [see comments]. Cell 1994;79: 573-82.
18. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-30.
19. Ohta M, Berd D, Shimizu M, et al. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int J Cancer 1996;65:762-7.
20. Okamoto A, Demetrick DJ, Spillare EA, et al. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 1994;91:11045-9.
21. Otterson GA, Khleif SN, Chen W, et al. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine. Oncogene 1995;11:1211-6.
22. el Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75: 817-25.
23. Michieli P, Chedid M, Lin D, et al. Induction of WAF1/CIPI by a p53-independent pathway. Cancer Res 1994;54:3391-5.
24. Harper JW, Adami GR, Wei N, et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
25. Harper JW, Elledge SJ, Keyomarsi K, et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995;6: 387-400.
26. Doglioni C, Pelosio P, Laurino L, et al. p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J Pathol 1996;179:248-53.
27. Shiohara M, el Deiry WS, Wada M, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84:3781-4.
28. Gao X, Chen YQ, Wu N, et al. Somatic mutations of the WAF1/CIP1 gene in human prostate cancer. Oncogene 1995;11:1395-8.
29. Prokocimer M, Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells:projection on the hematologic cell lineages. Blood 1994;84:2391-411.
30. Yunis JJ. Specific fine chromosomal defects in cancer: an overview. Hum Pathol 1981;12:503-15
31. Piris MA, Villuendas R, Martinez JC, et al. p53 expression in non-Hodgkin's lymphomas: a marker of p53 inactivation? Leuk Lymphoma 1995;17:35-42.
32. Haldar S, Negrini M, Monne M, et al. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54: 2095-7.
33. Silvestrini R, Veneroni S, Daidone MG, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
34. Basolo F, Pollina L, Fontanini G, et al. Apoptosis and proliferation in thyroid carcinoma: correlation with bcl-2 and p53 protein expression. Br J Cancer 1997;75:537-41.
35. Kock E, Naeser P. Retinoblastoma in Sweden 1958-1971. A clinical and histopathological study. Acta Ophthalmol Copenh 1979;57:344-50.
36. Mahoney MC, Burnett WS, Majerovics A, et al. The epidemiology of ophthalmic malignancies in New York State. Ophthalmology 1990;97:1143-7.
37. Pendergrass TW, Davis S. Incidence of retinoblastoma in the United States. Arch Ophthalmol 1980;98:1204-10.
38. Sanders BM, Draper GJ, Kingston JE. Retinoblastoma in Great Britain 1969-80: incidence, treatment, and survival. Br J Ophthalmol 1988;72:576-83.
39. Knudson AG Jr. The genetics of childhood cancer. Cancer 1975;35:1022-6.
40. Jensen OA. Malignant melanomas of the human uvea: 25-year follow-up of cases in Denmark, 1943-1952. Acta Ophthalmol Copenh 1982;60:161-82.
41. Horsman DE, Sroka H, Rootman J, et al. Monosomy 3 and isochromosome 8q in a uveal melanoma. Cancer Genet Cytogenet 1990;45:249-53.
42. Horsman DE, White VA. Cytogenetic analysis of uveal melanoma. Consistent occurrence of monosomy 3 and trisomy 8q. Cancer 1993;71:811-9.
43. Prescher G, Bornfeld N, Becher R. Nonrandom chromosomal abnormalities in primary uveal melanoma. J Natl Cancer Inst 1990;82:1765-9.
44. Prescher G, Bornfeld N, Horsthemke B, et al. Chromosomal aberrations defining uveal melanoma of poor prognosis [letter]. Lancet 1992;339:691-2.
45. Sisley K, Rennie IG, Cottam DW, et al. Cytogenetic findings in six posterior uveal melanomas:involvement of chromosomes 3, 6, and 8. Genes Chromosom Cancer 1990;2:205-9.
46. Sisley K, Cottam DW, Rennie IG, et al. Non-random abnormalities of chromosomes 3, 6, and 8 associated with posterior uveal melanoma. Genes Chromosomes Cancer 1992;5: 197-200.
47. Speicher MR, Prescher G, du Manoir S, et al. Chromosomal gains and losses in uveal melanomas detected by comparative genomic hybridization. Cancer Res 1994;54:3817-23.
48. McLean IW, Foster WD, Zimmerman LE, et al. Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol 1983;96:502-9.
49. Nork TM, Poulsen GL, Millecchia LL, et al. p53 regulates apoptosis in human retinoblastoma. Arch Ophthalmol 1997;115:213-9.
50. Norton AJ, Jordan S, Yeomans P. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 1994;173:371-9.
51. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133: 1710-5.
52. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984;32:219-29.
53. Fuchs U, Kivela T, Summanen P, et al. An immunohistochemical and prognostic analysis of cytokeratin expression in malignant uveal melanoma. Am J Pathol 1992;141:169-81.
54. Bechrakis NE, Bornfeld N, Schüler A, et al. Clinicopathological features of retinoblastoma after primary chemoreduction. Arch Ophthalmol 1998;(in press).
55. Lukas J, Muller H, Bartkova J, et al. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J Cell Biol 1994;125:625-38.
56. Nork TM, Schwartz TL, Doshi HM, et al. Retinoblastoma. Cell of origin. Arch Ophthalmol 1995;113:791-802.
57. Yuge K, Nakajima M, Uemura Y, et al. Immunohistochemical features of the human retina and retinoblastoma. Virchows Arch 1995;426:571-5.
58. Otterson GA, Kratzke RA, Coxon A, et al. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 1994;9:3375-8.
59. Yeager T, Stadler W, Belair C, et al. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res 1995;55:493-7.
60. Beltinger CP, White PS, Sulman EP, et al. No CDKN2 mutations in neuroblastomas. Cancer Res 1995;55:2053-5.
61. Sakaguchi M, Fujii Y, Hirabayashi H, et al. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer 1996;65:442-5.
62. Tsuzuki T, Tsunoda S, Sakaki T, et al. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas. Cancer 1996;78:287-93.
63. Janssen K, Kuntze J, Busse H, et al. p53 oncoprotein overexpression in choroidal melanoma. Mod Pathol 1996;9:267-72.
64. Tobal K, Warren W, Cooper CS, et al. Increased expression and mutation of p53 in choroidal melanoma. Br J Cancer 1992;66:900-4.
65. Wynford Thomas D. P53 in tumour pathology: can we trust immunocytochemistry? [Editorial] [see comments]. J Pathol 1992;166:329-30.
66. Costa MJ, Walls J, Ames P, et al. Transformation in recurrent ovarian granulosa cell tumors:Ki67 (MIB-1) and p53 immunohistochemistry demonstrates a possible molecular basis for the poor histopathologic prediction of clinical behavior. Hum Pathol 1996;27:274-81.
67. Golusinski W, Olofsson J, Szmeja Z, et al. p53, PCNA and Ki67 in laryngeal cancer. Pol J Pathol 1996;47:175-82.
68. Nawa G, Ueda T, Mori S, et al. Prognostic significance of Ki67 (MIB1) proliferation index and p53 over-expression in chondrosarcomas. Int J Cancer 1996;69:86-91.
69. Char DH, Huhta K, Waldman F. DNA cell cycle studies in uveal melanoma. Am J Ophthalmol 1989;107:65-72.
70. Mooy CM, de Jong PT, Van der Kwast TH, et al. Ki-67 immunostaining in uveal melanoma. The effect of preenucleation radiotherapy. Ophthalmology 1990;97:1275-80.
71. Schilling H, Weng Sehu K, Lee WR. A histologic study (including DNA quantification and Ki-67 labeling index) in uveal melanomas after brachytherapy with ruthenium plaques. Invest Ophthalmol Vis Sci 1997;38:2081-92.
72. Jay V, Yi Q, Hunter WS, Zielenska M. Expression of bcl-2 in uveal malignant melanoma. Arch Pathol Lab Med 1996;120: 497-8.
73. Mooy CM, Luyten GP, de Jong PT, et al. Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma. Am J Pathol 1995;147:1097-104.
74. Yang E, Korsmeyer SJ. Molecular thanatopsis:a discourse on the BCL2 family and cell death. Blood 1996;88:386-401.